Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants

Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results f...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jordan T. Russell, J. Lauren Ruoss, Diomel de la Cruz, Nan Li, Catalina Bazacliu, Laura Patton, Kelley Lobean McKinley, Timothy J. Garrett, Richard A. Polin, Eric W. Triplett, Josef Neu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a44
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6f3a6371d2554c1597cec7f371a14a44
record_format dspace
spelling oai:doaj.org-article:6f3a6371d2554c1597cec7f371a14a442021-12-02T13:56:56ZAntibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants10.1038/s41598-021-80982-62045-2322https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a442021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-80982-6https://doaj.org/toc/2045-2322Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results from the routine early antibiotic use in symptomatic preterm Neonates (REASON) study are presented. The REASON study is the first trial to randomize symptomatic preterm neonates to receive or not receive antibiotics in the first 48 h after birth. Using 16S rRNA sequencing of stool samples collected longitudinally for 91 neonates, the effect of such antibiotic use on microbiome diversity is assessed. The results illustrate that type of nutrition shapes the early infant gut microbiome. By integrating data for the gut microbiome, stool metabolites, stool immune markers, and inferred metabolic pathways, an association was discovered between Veillonella and the neurotransmitter gamma-aminobutyric acid (GABA). These results suggest early antibiotic use may impact the gut-brain axis with the potential for consequences in early life development, a finding that needs to be validated in a larger cohort. Trial Registration This project is registered at clinicaltrials.gov under the name “Antibiotic ‘Dysbiosis’ in Preterm Infants” with trial number NCT02784821.Jordan T. RussellJ. Lauren RuossDiomel de la CruzNan LiCatalina BazacliuLaura PattonKelley Lobean McKinleyTimothy J. GarrettRichard A. PolinEric W. TriplettJosef NeuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Jordan T. Russell
J. Lauren Ruoss
Diomel de la Cruz
Nan Li
Catalina Bazacliu
Laura Patton
Kelley Lobean McKinley
Timothy J. Garrett
Richard A. Polin
Eric W. Triplett
Josef Neu
Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
description Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results from the routine early antibiotic use in symptomatic preterm Neonates (REASON) study are presented. The REASON study is the first trial to randomize symptomatic preterm neonates to receive or not receive antibiotics in the first 48 h after birth. Using 16S rRNA sequencing of stool samples collected longitudinally for 91 neonates, the effect of such antibiotic use on microbiome diversity is assessed. The results illustrate that type of nutrition shapes the early infant gut microbiome. By integrating data for the gut microbiome, stool metabolites, stool immune markers, and inferred metabolic pathways, an association was discovered between Veillonella and the neurotransmitter gamma-aminobutyric acid (GABA). These results suggest early antibiotic use may impact the gut-brain axis with the potential for consequences in early life development, a finding that needs to be validated in a larger cohort. Trial Registration This project is registered at clinicaltrials.gov under the name “Antibiotic ‘Dysbiosis’ in Preterm Infants” with trial number NCT02784821.
format article
author Jordan T. Russell
J. Lauren Ruoss
Diomel de la Cruz
Nan Li
Catalina Bazacliu
Laura Patton
Kelley Lobean McKinley
Timothy J. Garrett
Richard A. Polin
Eric W. Triplett
Josef Neu
author_facet Jordan T. Russell
J. Lauren Ruoss
Diomel de la Cruz
Nan Li
Catalina Bazacliu
Laura Patton
Kelley Lobean McKinley
Timothy J. Garrett
Richard A. Polin
Eric W. Triplett
Josef Neu
author_sort Jordan T. Russell
title Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_short Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_full Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_fullStr Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_full_unstemmed Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_sort antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a44
work_keys_str_mv AT jordantrussell antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT jlaurenruoss antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT diomeldelacruz antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT nanli antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT catalinabazacliu antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT laurapatton antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT kelleylobeanmckinley antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT timothyjgarrett antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT richardapolin antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT ericwtriplett antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
AT josefneu antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
_version_ 1718392329027452928